10月28日，苑东生物涨5.47%，截至发稿，报55.30元/股，成交1.50亿元，换手率1.58%，总市值97.62亿 元。 资料显示，成都苑东生物制药股份有限公司位于四川省成都市双流区安康路8号，成立日期2009年6月1 日，上市日期2020年9月2日，公司主营业务涉及化学原料药和化学药制剂的研发、生产与销售。主营业 务收入构成为：制剂销售78.75%，原料药销售9.22%，技术服务及转让6.79%，CMO/CDMO4.01%，其 他1.22%。 从基金十大重仓股角度 中银证券健康产业混合（002938）成立日期2016年9月7日，最新规模1.59亿。今年以来收益41.95%，同 类排名1861/8155；近一年收益27.34%，同类排名3169/8029；成立以来收益138.44%。 中银证券健康产业混合（002938）基金经理为李明蔚。 截至发稿，李明蔚累计任职时间2年250天，现任基金资产总规模1.59亿元，任职期间最佳基金回 报-4.49%， 任职期间最差基金回报-4.49%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、 ...

Company Overview - Yuandong Biopharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on June 1, 2009, and listed on September 2, 2020. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The main revenue composition includes: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Stock Performance - On October 15, Yuandong's stock rose by 5.12%, reaching a price of 54.03 CNY per share, with a trading volume of 42.6 million CNY and a turnover rate of 0.46%. The total market capitalization is 9.538 billion CNY [1] Fund Holdings - The Guotou Ruijin Fund has a significant holding in Yuandong Biopharmaceutical, with the Guotou Ruijin Healthcare Mixed A Fund (000523) holding 98,300 shares, accounting for 2.96% of the fund's net value, making it the seventh-largest holding. The estimated floating profit today is approximately 258,600 CNY [2] - The Guotou Ruijin Healthcare Mixed A Fund was established on February 25, 2014, with a latest scale of 121 million CNY. Year-to-date returns are 31.89%, ranking 2270 out of 8161 in its category; the one-year return is 25.9%, ranking 2959 out of 8015; and since inception, the return is 150.74% [2]

Company Overview - Yuan Dong Bio's stock price increased by 5.22% on September 1, reaching 68.95 CNY per share, with a trading volume of 1.07 billion CNY and a turnover rate of 0.92%, resulting in a total market capitalization of 12.172 billion CNY [1] - The company has experienced a cumulative increase of 3.88% over the past three days [1] - Founded on June 1, 2009, and listed on September 2, 2020, Yuan Dong Bio specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The revenue composition of the company includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Fund Holdings - According to data, one fund under Industrial Bank, the Xingye Healthcare A Fund (011466), holds a significant position in Yuan Dong Bio, with 699,200 shares, accounting for 7.46% of the fund's net value, making it the largest holding [2] - The fund has realized a floating profit of approximately 2.3913 million CNY today, with a floating profit of 1.7131 million CNY during the three-day increase [2] - Xingye Healthcare A Fund was established on March 8, 2021, with a current scale of 249 million CNY, achieving a year-to-date return of 33.5% and a one-year return of 41.06% [2]